Cormorant Asset Management’s Odyssey Therapeutics ODTX Stock Holding History

Cormorant Asset Management’s Portfolio ODTX Stock Details ODTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.27M	Buy	+175,000	New	+$3.07M	0.17%	47

Other funds holding ODTX

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Lightspeed Management Company Menlo Park, California $2.4B AUM 7.07% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Adage Capital Partners

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Cormorant Asset Management's ODTX Position: Q2 2026 in Review

Cormorant Asset Management opened a new position in Odyssey Therapeutics (ODTX) in Q2 2026: 175,000 shares worth $3.27M. The stake represents 0.17% of the portfolio and ranks #47 among its holdings.

50 funds tracked by Wall St. Rank hold ODTX as of Q2 2026.

Cormorant Asset Management held 175,000 shares of Odyssey Therapeutics worth $3.27M as of Q2 2026.
Odyssey Therapeutics was a new Cormorant Asset Management position in Q2 2026.
Odyssey Therapeutics made up 0.17% of Cormorant Asset Management's portfolio in Q2 2026, its #47 holding.
50 funds tracked by Wall St. Rank held Odyssey Therapeutics as of Q2 2026.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.